Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.

Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer.

Uzunkoy A, Dilmec F, Ozgonul A, van Kuilenburg AB, Akkafa F.

Anticancer Res. 2007 Nov-Dec;27(6B):3899-902.

2.

5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients.

Sulzyc-Bielicka V, Bińczak-Kuleta A, Pioch W, Kładny J, Gziut K, Bielicki D, Ciechanowicz A.

Pharmacol Rep. 2008 Mar-Apr;60(2):238-42.

3.

[Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].

Kralovánszky J, Adleff V, Hitre E, Pap E, Réti A, Komlósi V, Budai B.

Magy Onkol. 2007;51(2):113-25. Epub 2007 Jul 29. Hungarian.

4.

Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.

Paré L, Paez D, Salazar J, Del Rio E, Tizzano E, Marcuello E, Baiget M.

Br J Clin Pharmacol. 2010 Aug;70(2):268-72. doi: 10.1111/j.1365-2125.2010.03683.x.

5.

High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.

Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH.

Pharmacogenetics. 2002 Oct;12(7):555-8.

PMID:
12360106
6.

Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population.

Hsiao HH, Yang MY, Chang JG, Liu YC, Liu TC, Chang CS, Chen TP, Lin SF.

Cancer Chemother Pharmacol. 2004 May;53(5):445-51.

PMID:
15132136
7.

Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.

Ofverholm A, Arkblad E, Skrtic S, Albertsson P, Shubbar E, Enerbäck C.

Clin Biochem. 2010 Feb;43(3):331-4. doi: 10.1016/j.clinbiochem.2009.09.024. Epub 2009 Oct 12.

PMID:
19822137
8.

Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.

van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, van Gennip AH.

Clin Cancer Res. 2001 May;7(5):1149-53.

11.

Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.

van Kuilenburg AB.

Eur J Cancer. 2004 May;40(7):939-50. Review.

PMID:
15093568
12.
13.

Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients.

He YF, Wei W, Zhang X, Li YH, Li S, Wang FH, Lin XB, Li ZM, Zhang DS, Huang HQ, Hu B, Jiang WQ.

J Clin Pharm Ther. 2008 Jun;33(3):307-14. doi: 10.1111/j.1365-2710.2008.00898.x.

PMID:
18452418
15.

Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.

Amstutz U, Farese S, Aebi S, Largiadèr CR.

Pharmacogenomics. 2009 Jun;10(6):931-44. doi: 10.2217/pgs.09.28.

16.

Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients.

Salgueiro N, Veiga I, Fragoso M, Sousa O, Costa N, Pellon ML, Sanches E, dos Santos JG, Teixeira MR, Castedo S.

Genet Med. 2004 Mar-Apr;6(2):102-7.

PMID:
15017333
17.

Low Incidence of the DPD IVS14+1G>A Polymorphism in Jordanian Breast and Colorectal Cancer patients

Al-Khateeb M, Awidi A, Al-Hadidi K, Battah A.

Asian Pac J Cancer Prev. 2017 Jun 25;18(6):1651-1654.

18.

Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population.

Ben Fredj R, Gross E, Chouchen L, B'Chir F, Ben Ahmed S, Neubauer S, Kiechle M, Saguem S.

C R Biol. 2007 Oct;330(10):764-9. Epub 2007 Sep 7.

PMID:
17905396
19.

DPYD*2A mutation: the most common mutation associated with DPD deficiency.

Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB.

Cancer Chemother Pharmacol. 2007 Sep;60(4):503-7. Epub 2006 Dec 13.

PMID:
17165084
20.

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.

Amstutz U, Farese S, Aebi S, Largiadèr CR.

J Exp Clin Cancer Res. 2008 Oct 20;27:54. doi: 10.1186/1756-9966-27-54.

Supplemental Content

Support Center